The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness
• By Michael McCaughan
Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.
By Michael McCaughan
When Pharmaceutical Research & Manufacturers of America CEO Billy Tauzin talks about the dangers of government-run cost effectiveness systems, he...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.
Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”